EA201892443A1 - Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови - Google Patents
Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток кровиInfo
- Publication number
- EA201892443A1 EA201892443A1 EA201892443A EA201892443A EA201892443A1 EA 201892443 A1 EA201892443 A1 EA 201892443A1 EA 201892443 A EA201892443 A EA 201892443A EA 201892443 A EA201892443 A EA 201892443A EA 201892443 A1 EA201892443 A1 EA 201892443A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- blood cells
- antibodies against
- pharmaceutical compositions
- clinical use
- against antigen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662328959P | 2016-04-28 | 2016-04-28 | |
| PCT/US2017/029802 WO2017189827A1 (en) | 2016-04-28 | 2017-04-27 | Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201892443A1 true EA201892443A1 (ru) | 2019-04-30 |
Family
ID=58672794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201892443A EA201892443A1 (ru) | 2016-04-28 | 2017-04-27 | Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови |
Country Status (16)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA49962A (fr) * | 2017-08-22 | 2020-07-01 | Biogen Ma Inc | Procédés de purification d'anticorps présentant des agrégats réduits à poids moléculaire élevé |
| EP3823594B1 (en) | 2018-07-19 | 2025-02-05 | Ichnos Sciences S.A. | Liquid antibody formulation |
| KR200494676Y1 (ko) | 2020-08-04 | 2021-12-01 | (주) 티나인 | 버튼식 헤어 염색기 |
| PE20231678A1 (es) | 2020-12-03 | 2023-10-19 | Biogen Ma Inc | Metodos de tratamiento del lupus eritematoso cutaneo y lupus eritematoso sistemico |
| CN118055781A (zh) | 2021-08-09 | 2024-05-17 | 株式会社茵温特拉 | 注入到生物体内后以不被巨噬细胞吞噬和/或不被代谢分解的状态通过肾脏由尿液排出的纳米结构物 |
| TW202400652A (zh) * | 2022-05-25 | 2024-01-01 | 大陸商映恩生物製藥（蘇州）有限公司 | 抗ｂｄｃａ２抗體及其用途 |
| EP4643887A1 (en) * | 2022-12-28 | 2025-11-05 | Duality Biologics (Shanghai) Co., Ltd. | Anti-bdca2 antibody-drug conjugate and use thereof |
| WO2025067469A1 (zh) * | 2023-09-28 | 2025-04-03 | 南京维立志博生物科技股份有限公司 | Bdca2单克隆抗体及其和taci组成的融合蛋白及其方法和用途 |
| CN118638234B (zh) * | 2024-07-04 | 2025-10-14 | 杭州博之锐生物制药有限公司 | 抗bdca2抗体及其制备方法和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4869064B2 (ja) * | 2003-04-04 | 2012-02-01 | ジェネンテック， インコーポレイテッド | 高濃度抗体及びタンパク質製剤 |
| HUE047874T2 (hu) * | 2012-12-10 | 2020-05-28 | Biogen Ma Inc | Vér dendritikus sejt antigén 2 elleni antitestek és alkalmazásuk |
-
2017
- 2017-04-27 MA MA044763A patent/MA44763A/fr unknown
- 2017-04-27 AU AU2017258191A patent/AU2017258191B2/en active Active
- 2017-04-27 WO PCT/US2017/029802 patent/WO2017189827A1/en not_active Ceased
- 2017-04-27 CA CA3022116A patent/CA3022116A1/en active Pending
- 2017-04-27 JP JP2018556446A patent/JP7045327B2/ja active Active
- 2017-04-27 CN CN201780032450.0A patent/CN109475623B/zh active Active
- 2017-04-27 KR KR1020257018429A patent/KR20250088784A/ko active Pending
- 2017-04-27 EP EP17722325.2A patent/EP3448425A1/en active Pending
- 2017-04-27 NZ NZ747504A patent/NZ747504A/en unknown
- 2017-04-27 KR KR1020227005469A patent/KR20220028150A/ko not_active Ceased
- 2017-04-27 US US16/095,475 patent/US20190284281A1/en not_active Abandoned
- 2017-04-27 KR KR1020247007023A patent/KR20240033168A/ko not_active Ceased
- 2017-04-27 MX MX2018012945A patent/MX2018012945A/es unknown
- 2017-04-27 CN CN202310503830.5A patent/CN116850282A/zh active Pending
- 2017-04-27 KR KR1020187034043A patent/KR102366547B1/ko active Active
- 2017-04-27 NZ NZ787392A patent/NZ787392A/en unknown
- 2017-04-27 KR KR1020247035142A patent/KR20240159012A/ko not_active Ceased
- 2017-04-27 BR BR112018072125-5A patent/BR112018072125A2/pt active Search and Examination
- 2017-04-27 EA EA201892443A patent/EA201892443A1/ru unknown
-
2018
- 2018-10-22 IL IL262514A patent/IL262514B2/en unknown
- 2018-10-23 MX MX2025000037A patent/MX2025000037A/es unknown
- 2018-10-23 MX MX2023008075A patent/MX2023008075A/es unknown
- 2018-10-26 PH PH12018502278A patent/PH12018502278A1/en unknown
- 2018-11-22 CO CONC2018/0012506A patent/CO2018012506A2/es unknown
-
2022
- 2022-03-18 JP JP2022043702A patent/JP2022084782A/ja active Pending
-
2024
- 2024-01-10 JP JP2024001801A patent/JP2024038308A/ja active Pending
- 2024-05-15 AU AU2024203240A patent/AU2024203240A1/en active Pending
-
2025
- 2025-02-21 US US19/060,474 patent/US20250289895A1/en active Pending
- 2025-06-17 IL IL321561A patent/IL321561A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201892443A1 (ru) | Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови | |
| AR110645A1 (es) | Anticuerpos anti-hla-g y uso de los mismos | |
| CY1125326T1 (el) | Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων. | |
| BR112018068748A2 (pt) | composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto | |
| CY1122060T1 (el) | Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων | |
| EA201690618A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| MX375752B (es) | Inhibidores de tirosina quinasa de bruton. | |
| EA201891186A1 (ru) | Антитела, нейтрализующие вирус иммунодефицита человека | |
| EA201890006A1 (ru) | Применение экзосом для лечения болезни | |
| EA201890530A1 (ru) | Конъюгаты антитела к dll3 и лекарственного средства и способы их применения | |
| EA201692177A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| MX2018010032A (es) | Formulaciones de antagonista de il-6 y sus usos. | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| EA201692201A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| EA201790239A1 (ru) | Молекула-носитель для антигенов | |
| WO2016196776A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| ZA202103867B (en) | Tubulysins and protein-tubulysin conjugates | |
| CY1122882T1 (el) | Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου | |
| EA201991951A1 (ru) | Низковязкие высококонцентрированные составы на основе эволокумаба и способы их получения | |
| EA202090063A1 (ru) | Композиции и способы для лечения таупатий | |
| EA201791067A1 (ru) | Способы лечения субъектов с синдромом прадера-вилли или синдромом смита-магениса | |
| WO2018033941A3 (en) | Pharmaceutical compositions of ibrutinib | |
| EA202091563A1 (ru) | Человеческие антитела к гемагглютинину вируса гриппа | |
| MX2018005226A (es) | Formulaciones de anticuerpo anti-factor d. | |
| AR109279A1 (es) | Anticuerpos anti plazomicina y métodos de uso de los mismos |